Precision BioSciences (NASDAQ:DTIL) Issues Earnings Results

Precision BioSciences (NASDAQ:DTIL) posted its quarterly earnings data on Thursday. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.46), FiscalAI reports. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 67.70%.

Precision BioSciences Stock Performance

NASDAQ DTIL traded up $0.07 on Friday, hitting $7.49. 240,103 shares of the company’s stock were exchanged, compared to its average volume of 341,234. The firm has a market cap of $193.24 million, a price-to-earnings ratio of -2.67 and a beta of 1.27. The firm’s 50-day moving average price is $7.36 and its two-hundred day moving average price is $6.33. Precision BioSciences has a fifty-two week low of $3.53 and a fifty-two week high of $9.62. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02.

Wall Street Analysts Forecast Growth

DTIL has been the topic of a number of recent research reports. JonesTrading restated a “buy” rating and issued a $30.00 price objective on shares of Precision BioSciences in a research note on Friday, April 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday. Oppenheimer initiated coverage on Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Finally, Wall Street Zen downgraded Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Precision BioSciences presently has an average rating of “Moderate Buy” and an average target price of $32.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DTIL. Geode Capital Management LLC lifted its stake in shares of Precision BioSciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the period. Lynx1 Capital Management LP grew its stake in Precision BioSciences by 0.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after acquiring an additional 6,545 shares during the last quarter. Quarry LP grew its position in shares of Precision BioSciences by 15.1% in the fourth quarter. Quarry LP now owns 68,311 shares of the company’s stock valued at $284,000 after purchasing an additional 8,936 shares during the last quarter. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences during the 4th quarter worth approximately $43,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences during the fourth quarter worth $52,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.